Get started
Author

Lígia Yukie Sassaki

Observed names: L Sassaki, L Y Sassaki, L Yukie Sassaki, L. Sassaki, L. Y SASSAKI, L. Y. Sassaki, L.Y. Sassaki, Ligia Sassaki, Ligia Y Sassaki, Ligia Y. Sassaki, Ligia Yukie SASSAKI, Ligia Yukie Sassak, Ligia Yukie Sassaki, Ligia, Sassaki, Ligia Yukie Sassaki, Lígia Sassaki, Lígia Y. Sassaki, Lígia Yukie SASSAKI, Sassaki LY, Sassaki Ligia, Sassaki, L., Sassaki, Ligia, Sassaki, Ligia Yukie, Sassaki,Lígia Yukie
ORCID: 0000-0002-7319-8906
Observed ORCID: 0000-0002-7319-8906
OpenAlex ID: A5013244630
Gut microbiota, inflammatory bowel disease and colorectal cancer
2022 · Ana Elisa Valencise Quaglio, Thais Gagno Grillo, et al. · World Journal of Gastroenterology · 463
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
2023 · Brian G Feagan, Bruce E Sands, et al. · ˜The œLancet. Gastroenterology & hepatology · 246
Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil
2009 · Carlos Roberto Victoria, Ligia Yukie Sassak, et al. · Arquivos de Gastroenterologia · 156
PDF
Risankizumab for Ulcerative Colitis
2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134
PDF
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
2024 · Marc Ferrante, Marc Ferrante, et al. · The Lancet · 119
PDF
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
2021 · Laurent Peyrin-Biroulet, Ailsa Hart, et al. · ˜The œLancet. Gastroenterology & hepatology · 97
PDF
Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil
2019 · Rogerio S Parra, Julio MF Chebli, et al. · World Journal of Gastroenterology · 90
PDF
Inflammatory bowel disease epidemiology in São Paulo State, Brazil
2018 · Rodrigo Galhardi Gasparini, Lígia Yukie Sassaki, et al. · Clinical and Experimental Gastroenterology · 50
PDF
Cardiovascular Risk in Individuals with Inflammatory Bowel Disease
2020 · Robertha Baccaro Biondi, Pericles Sidnei Salmazo, et al. · Clinical and Experimental Gastroenterology · 48
PDF
Body Composition in Patients With Crohn’s Disease and Ulcerative Colitis
2017 · Ivi Ribeiro BACK, Sonia Silva MARCON, et al. · Arquivos de Gastroenterologia · 41
PDF
Sexual Dysfunction in Inflammatory Bowel Disease: What the Specialist Should Know and Ask
2021 · Edith Perez de Arce, Rodrigo Quera, et al. · International Journal of General Medicine · 39
PDF
Intestinal Microbiota and miRNA in IBD: A Narrative Review about Discoveries and Perspectives for the Future
2023 · Ellen Cristina Souza de Oliveira, Ana Elisa Valencise Quaglio, et al. · International Journal of Molecular Sciences · 37
PDF
Ultra-Processed Foods, Gut Microbiota, and Inflammatory Bowel Disease: A Critical Review of Emerging Evidence
2025 · Amanda Luísa Spiller, Beatriz Gabriela da Costa, et al. · Nutrients · 34
PDF
Mucosa-associated but not luminal Escherichia coli is augmented in Crohn’s disease and ulcerative colitis
2012 · Helton Luis de Souza, Vanessa R de Carvalho, et al. · Gut Pathogens · 33
PDF
Escherichia coli from Crohn’s disease patient displays virulence features of enteroinvasive (EIEC), enterohemorragic (EHEC), and enteroaggregative (EAEC) pathotypes
2015 · Ana Carolina da Silva Santos, Fernando Gomes Romeiro, et al. · Gut Pathogens · 32
PDF
Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment
2022 · Luiz Fernando Norcia, Erika Mayumi Watanabe, et al. · Hepatic Medicine Evidence and Research · 28
PDF
Analysis of Risk Factors and Postoperative Complications in Patients With Crohn’s Disease
2018 · Rogério SAAD HOSSNE, Ligia Yukie SASSAKI, et al. · Arquivos de Gastroenterologia · 25
PDF
Risk factors for ulcerative colitis-associated colorectal cancer
2020 · Elen Farinelli de Campos Silva, Julio Pinheiro Baima, et al. · Medicine · 23
Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil
2021 · Cyrla Zaltman, Rogério Serafim Parra, et al. · World Journal of Gastroenterology · 22
Inflammatory Bowel Disease Care in Brazil: How It Is Performed, Obstacles and Demands From the Physicians’ Perspective
2020 · Eduardo Garcia VILELA, Henrique Carvalho ROCHA, et al. · Arquivos de Gastroenterologia · 22
PDF
Fecal calprotectin and endoscopic scores: The cornerstones in clinical practice for evaluating mucosal healing in inflammatory bowel disease
2024 · Marcia Henriques de Magalhães Costa, Ligia Yukie Sassaki, et al. · World Journal of Gastroenterology · 20
PDF
Nutritional intake according to injury extent in ulcerative colitis patients
2013 · A. P. S. Urbano, L. Y. Sassaki, et al. · Journal of Human Nutrition and Dietetics · 19
MicroRNAs expression influence in ulcerative colitis and Crohn's disease: A pilot study for the identification of diagnostic biomarkers
2021 · Ana Elisa Valencise Quaglio, Felipe Jose Santaella, et al. · World Journal of Gastroenterology · 17
Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature
2021 · Thais Gagno Grillo, Luciana Rocha Almeida, et al. · World Journal of Clinical Cases · 17
Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
2023 · Thais Gagno Grillo, da Silva Mazeto Pupo Silveira Caroline Ferreira, et al. · World Journal of Cardiology · 16
PDF
Works count: 227
Citation count: 2,241
H-index: 20
I10-index: 43
Year
Topic
Type